Aktienanalyse zu Rockwell Medical Inc (RMTI)RMTIRockwell Medical Inc

Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rockwell Medical Inc (RMTI) appears to be a good buy right now, trading at $7.75 with a significant upside potential. The stock has a forward P/E ratio of 22.37, indicating growth expectations despite current losses. Additionally, the recent acquisition of Vantive's hemodialysis business for $125 million could enhance revenue streams, which is crucial as the company reported a gross margin of 18.24% in Q2 2026, showing improvement. However, the main risk is the negative earnings per share (EPS) of -0.34 reported in the last earnings call, highlighting ongoing financial challenges.

3 analysts cover RMTI: 1 rate it Buy, 1 Hold and 1 Sell. The average price target is 3.75.